Premium
OBINUTUZUMAB THERAPY IN PATIENTS WITH MARGINAL ZONE AND MANTLE CELL LYMPHOMA
Author(s) -
Hughes M.E.,
Suen C.,
Namoglu E.,
Schuster S.J.,
Svoboda J.,
Loren A.,
Nasta S.D.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.74_2631
Subject(s) - medicine , mantle cell lymphoma , rituximab , obinutuzumab , follicular lymphoma , bendamustine , marginal zone b cell lymphoma , progression free survival , oncology , discontinuation , regimen , salvage therapy , gastroenterology , lymphoma , marginal zone , chemotherapy , immunology , b cell , antibody
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom